Nomad Foods GLP-1 Podcast
13 March 2026Using the latest IGD GLP-1 insight, we unpack the rise of weight loss medications and their growing impact on the global food landscape.
IGD was delighted to be a recent guest of the Nomad Foods Podcast. In the podcast, Tom Wakeman, Insight Director at IGD, unpacks the rapid rise of GLP‑1 medication, including Mounjaro, Wegovy and Ozempic, and their growing impact on the global food landscape.
Tom explains what GLP‑1 drugs are, why adoption has accelerated, and how they’re already reshaping consumer behaviour. He discusses the impact of weight loss drugs on users' calorie intake and snacking habits, how appetite suppressants are impacting our commercial reality, whether by informing shoppers' retailer choices or their responses to product innovation.
Using the latest IGD research and insights, Tom explores the implications for retailers and manufacturers, the opportunities emerging across categories, and how organisations can respond to this long‑term shift in how people eat.
Listen to our podcast:
GLP-1 insights and solutions
Stay up to date with our latest research, impartial analysis, business intelligence, and guidance on this evolving trend.